Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. - Wikidata - wikimedia - TriplyDB

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

http://www.wikidata.org/entity/Q34384793

about

Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania HIV and co-infections.HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.The role of HBsAg levels in the current management of chronic HBV infection.Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis.

P2860

Q33773235-3526FE3D-1FE8-41A8-8AC0-9C09F16EB385 Q34613499-FD1F2281-19C5-4C7A-A2CC-0EA28DB8A744 Q36970184-2706AA7D-5809-4213-AD77-9D107EC2DB5C Q39425755-8D9AE9D6-45EE-450E-A9C1-5E2342F585DC Q42233095-E02FB59B-37DA-46F3-9B14-3F3CA9AA1012 Q42263556-B27EC73D-37D0-40BB-9568-2CD363CEF634 Q42360905-195BE621-7278-4AB5-8E33-A9916DF638E2 Q46107250-3B7010C5-E8C1-43B4-A8EE-94F8D27ABB83

P2860

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

http://www.wikidata.org/entity/Q34384793

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@ast

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@en

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@nl

type

label

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@ast

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@en

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@nl

prefLabel

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@ast

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@en

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@nl

P1433

Q34384793-C2770178-2AB5-462F-B742-C9139A005E69

P1476

Q34384793-039BB374-3F6A-4B60-9D8F-498F1AEAA4EC

P2093

Q34384793-0102CD48-1CD0-430C-AE06-E725016FE97D

Q34384793-26DE81B8-6F65-4034-B590-B2A9CB6642A3

Q34384793-4BA2945F-3DC9-4A23-B56D-CF1B5F0483F9

Q34384793-69949261-5B1C-4F3C-A814-D9B66361B83D

Q34384793-715AA87B-D634-4010-B823-51EC7FD3DA9E

Q34384793-7CA5AE66-B0B7-4091-B7D4-60D28FF63DB8

Q34384793-8828A623-77BE-4514-AA4F-F930B4F98E97

Q34384793-9A488D72-EAD9-4F43-82F8-6EA3F8FF45F3

Q34384793-9B11BC20-2259-4C6C-9E0A-84C120270BC2

Q34384793-D6BF7BFA-2EBB-4BFE-BA7D-154AB70B9DCC

P2860

Q34384793-0796052F-6A2F-4ACF-BACD-AC1A76C36E61

Q34384793-0FD9854F-ADB5-4AF5-8AEA-B4E8BB3C1890

Q34384793-1C3B549B-CBAA-47C2-A339-82DBCF597139

Q34384793-4AD7BB86-0ECE-46DD-9AC9-69AD5443D987

Q34384793-55D470F1-9907-4A56-A2DB-2876696E7608

Q34384793-569DF675-60C3-43C4-8A74-034A46217A78

Q34384793-577C979B-B259-479B-94ED-C0F050D297BB

Q34384793-67CD1EC5-5379-4525-87CF-9A02357D0C31

Q34384793-6F126B41-6814-4FF3-BC28-E6EED892EE91

Q34384793-7A788CB5-F7C3-4E07-A3FA-D6D1FE170F83

P304

Q34384793-03F07528-ABDE-4E4A-8E86-C5BE34E88219

P31

Q34384793-1CE331FB-ABA7-4CEE-8365-9BB063BE0664

P356

Q34384793-8704DA82-B365-41A3-88E6-33298B67349D

P407

Q34384793-2C42C8EB-AA71-424A-80B8-3D00CE80AB5B

P433

Q34384793-AF574D01-A1FF-4BA0-8249-4418A43B3033

P478

Q34384793-754CBDB0-5940-4BDE-B61C-79400CD0AEDC

P50

Q34384793-39CDE2B8-16CC-4CF4-9BB8-A0CC9F9D989B

Q34384793-5D71DE73-D2CE-4CA3-9E87-892753D674FF

Q34384793-FA9C4EBB-74CE-4C26-A022-FED84A50BC83

P577

Q34384793-97B9FD07-1FFB-44FB-9FEF-DCCFDF98F16A

P5875

Q34384793-BB86AAB1-5786-4F6C-AE5A-090CFDEE4E4D

P698

Q34384793-7267E105-6DFB-4734-B553-FAA1AF707777

P932

Q34384793-2B0365C6-44F7-474D-94F4-9D47C1F5006D

P356

JOURNAL.PONE.0043143

P1433

P1476

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

@en

P2093

Berit Anna Payer

http://www.w3.org/2001/XMLSchema#string

Dirk Meyer-Olson

http://www.w3.org/2001/XMLSchema#string

Heiner Wedemeyer

http://www.w3.org/2001/XMLSchema#string

Jerzy Jaroszewicz

http://www.w3.org/2001/XMLSchema#string

Markus Cornberg

http://www.w3.org/2001/XMLSchema#string

Martin Vogel

http://www.w3.org/2001/XMLSchema#string

Matthias Stoll

http://www.w3.org/2001/XMLSchema#string

Michael P Manns

http://www.w3.org/2001/XMLSchema#string

Patrick Ingiliz

http://www.w3.org/2001/XMLSchema#string

Reinhold E Schmidt

http://www.w3.org/2001/XMLSchema#string

P2860

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment.

Epidemiology of viral hepatitis and HIV co-infection.

Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses.

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.

Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.

P304

e43143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0043143

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Markus Peck-Radosavljevic

Jürgen Rockstroh

P577

2012-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230699958

http://www.w3.org/2001/XMLSchema#string

P698

22905219

http://www.w3.org/2001/XMLSchema#string

P932

3419648

http://www.w3.org/2001/XMLSchema#string